however, clinicians and caregivers will significantly benefit from identifying patients that may potentially respond to these treatments
& Turco, M
GLP-1R agonists have demonstrated interesting results in individuals with ASP (with or without OSA), while results from future RCTs and post hoc analyses from other published RCTs are anticipated (Table I)
Psychiatry Should Start Acting Like It Written by Will Sauv, MD & Annete Bosworth, MD The short answer: GLP-1 receptors in the brain's reward circuits may explain why these drugs reduce cravings for alcohol, nicotine, and other substances not just food
Beauchamp A, Yee Y, Darwin BC, Raznahan A, Mars RB, Lerch JP
None of this substitutes for guidance from a qualified professional, and none of it is a recommendation to run any particular cycle